News Release Distributed 06/01/10

BATON ROUGE, La. – Two new people have joined the management team and one new person has been added to the Board of Directors of TransGenRx Inc., a bio-pharmaceutical manufacturing company started through technology developed at the Louisiana State University AgCenter.

Victor S. Filatov of London, England, has been named the chief financial officer, and Philippe Tremml of Zurich, Switzerland, will take on the new position of chief operating officer of European operations.

The new board member is Douglas H. Altschuler of New York, N.Y.

Filatov, a former chief operating officer with Citigroup, has more than 25 years of experience in asset management and investment banking. An economist by training with two degrees from the University of Pennsylvania, he is a former president of Capula Investment Management in London.

Tremml will oversee commercialization in Europe. He is general manager of Biologicals International, a consulting firm dedicated to the development and commercialization of biosimilars and biologicals. He holds a bachelor’s degree in economics and doctorate in neuroscience from the University of Zurich.

Altschuler has been chief executive officer, chief operating officer and general counsel for both private and publicly traded biotechnology companies. A law graduate of the University of Arizona, he has a track record of successful interactions with the Food and Drug Administration and leaders in the medical industry in the establishment of start-up companies.

“The addition of these leaders to the management team will help execute the strategy for commercial development. We are pleased to be associated with this dynamic and innovative company,” said William B. Richardson, chancellor of the LSU AgCenter.

TransGenRx, a company established in 2002, licenses technology developed by Dr. Richard Cooper, professor in the LSU AgCenter’s Department of Veterinary Science. The LSU AgCenter jointly holds some of the patents to the technology, which involves producing proteins in living cells for use in the pharmaceutical industry.

Other members of the TransGenRx board in addition to Cooper, the chief science officer and executive vice president, are Bill Fioretti, chief executive officer; John Gallagher, general counsel; David Barley and Robert Kenney.

TransGenRx is located at the Louisiana Emerging Technology Center on the LSU campus in Baton Rouge.